140 related articles for article (PubMed ID: 15666998)
61. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells.
Ali JL; Lagasse BJ; Minuk AJ; Love AJ; Moraya AI; Lam L; Arthur G; Gibson SB; Morrison LC; Werbowetski-Ogilvie TE; Fu Y; Nachtigal MW
Int J Cancer; 2015 Mar; 136(5):E455-69. PubMed ID: 25227893
[TBL] [Abstract][Full Text] [Related]
62. Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro.
Connolly K; Mitter R; Muir M; Jodrell D; Guichard S
Cancer Chemother Pharmacol; 2009 Jul; 64(2):307-16. PubMed ID: 19034449
[TBL] [Abstract][Full Text] [Related]
63. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
64. Cytotoxicity of isoflavones and biflavonoids from Ormocarpum kirkii towards multi-factorial drug resistant cancer.
Adem FA; Mbaveng AT; Kuete V; Heydenreich M; Ndakala A; Irungu B; Yenesew A; Efferth T
Phytomedicine; 2019 May; 58():152853. PubMed ID: 30836216
[TBL] [Abstract][Full Text] [Related]
65. Activin receptor-like kinase 7 induces apoptosis through up-regulation of Bax and down-regulation of Xiap in normal and malignant ovarian epithelial cell lines.
Xu G; Zhou H; Wang Q; Auersperg N; Peng C
Mol Cancer Res; 2006 Apr; 4(4):235-46. PubMed ID: 16603637
[TBL] [Abstract][Full Text] [Related]
66. The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells.
Wang X; Yang B; Ma B
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1025-1031. PubMed ID: 27686228
[TBL] [Abstract][Full Text] [Related]
67. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro.
Bilim V; Kasahara T; Hara N; Takahashi K; Tomita Y
Int J Cancer; 2003 Jan; 103(1):29-37. PubMed ID: 12455050
[TBL] [Abstract][Full Text] [Related]
68. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
Lee YY; Jeon HK; Hong JE; Cho YJ; Ryu JY; Choi JJ; Lee SH; Yoon G; Kim WY; Do IG; Kim MK; Kim TJ; Choi CH; Lee JW; Bae DS; Kim BG
Oncotarget; 2015 Oct; 6(33):35040-50. PubMed ID: 26418900
[TBL] [Abstract][Full Text] [Related]
69. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity.
Liston P; Fong WG; Kelly NL; Toji S; Miyazaki T; Conte D; Tamai K; Craig CG; McBurney MW; Korneluk RG
Nat Cell Biol; 2001 Feb; 3(2):128-33. PubMed ID: 11175744
[TBL] [Abstract][Full Text] [Related]
70. Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel.
Britten RA; Klein K
Anticancer Drugs; 2000 Jul; 11(6):439-43. PubMed ID: 11001384
[TBL] [Abstract][Full Text] [Related]
71. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
72. Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells.
Marth C; Zeimet AG; Widschwendter M; Ludescher C; Kaern J; Tropé C; Gastl G; Daxenbichler G; Dapunt O
Cancer Res; 1997 Sep; 57(17):3818-22. PubMed ID: 9288793
[TBL] [Abstract][Full Text] [Related]
73. [Inhibition of ovarian cancer growth by small interfering RNA targeting X-linked inhibitor of apoptosis gene].
Ma JJ; Chen BL; Xin XY
Zhonghua Fu Chan Ke Za Zhi; 2007 Feb; 42(2):124-8. PubMed ID: 17442189
[TBL] [Abstract][Full Text] [Related]
74. Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells.
Moraya AI; Ali JL; Samadder P; Liang L; Morrison LC; Werbowetski-Ogilvie TE; Ogunsina M; Schweizer F; Arthur G; Nachtigal MW
J Exp Clin Cancer Res; 2017 May; 36(1):67. PubMed ID: 28499442
[TBL] [Abstract][Full Text] [Related]
75. Phenoxodiol: isoflavone analog with antineoplastic activity.
Choueiri TK; Wesolowski R; Mekhail TM
Curr Oncol Rep; 2006 Mar; 8(2):104-7. PubMed ID: 16507219
[TBL] [Abstract][Full Text] [Related]
76. Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel.
Kim SM; Lee SY; Yuk DY; Moon DC; Choi SS; Kim Y; Han SB; Oh KW; Hong JT
Arch Pharm Res; 2009 May; 32(5):755-65. PubMed ID: 19471891
[TBL] [Abstract][Full Text] [Related]
77. Phenoxodiol treatment alters the subsequent response of ENOX2 (tNOX) and growth of hela cells to paclitaxel and cisplatin.
Morré DJ; McClain N; Wu LY; Kelly G; Morré DM
Mol Biotechnol; 2009 May; 42(1):100-9. PubMed ID: 19156549
[TBL] [Abstract][Full Text] [Related]
78. Increase in docetaxel-resistance of ovarian carcinoma-derived RMG-1 cells with enhanced expression of Lewis Y antigen.
Zhang F; Liu J; Lin B; Liu Q; Zhao Y; Zhu L; Hao Y; Zhang S; Iwamori M
Int J Mol Sci; 2011; 12(11):7323-34. PubMed ID: 22174601
[TBL] [Abstract][Full Text] [Related]
79. ECTO-NOX target for the anticancer isoflavene phenoxodiol.
Morré DJ; Chueh PJ; Yagiz K; Balicki A; Kim C; Morré DM
Oncol Res; 2007; 16(7):299-312. PubMed ID: 17518268
[TBL] [Abstract][Full Text] [Related]
80. Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines.
Mahoney S; Arfuso F; Rogers P; Hisheh S; Brown D; Millward M; Dharmarajan A
J Biosci; 2012 Mar; 37(1):73-84. PubMed ID: 22357205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
